Rchr
J-GLOBAL ID:201301034308637959   Update date: Mar. 24, 2024

Ryohei Katayama

カタヤマ リョウヘイ | Ryohei Katayama
Affiliation and department:
Job title: 部長
Homepage URL  (1): http://kaken.nii.ac.jp/d/r/60435542.ja.html
Research field  (2): Tumor biology ,  Pathobiochemistry
Research keywords  (9): cancer immunotherapy ,  molecular targeted cancer therapy ,  多剤耐性 ,  がん幹細胞 ,  ABCトランスポーター ,  acquired resistance ,  cancer ,  薬学 ,  cellular signal transduction
Research theme for competitive and other funds  (16):
  • 2022 - 2026 Searching druggable target sites by developing refined molecular dynamic simulations
  • 2022 - 2024 Oct4陽性肺癌幹細胞マウスモデルの樹立と癌幹細胞を根絶する革新的治療法の開発
  • 2020 - 2024 臨床がんの遺伝子情報維持に必要な物理化学的因子の解明とがん個別化医療への応用
  • 2020 - 2022 Molecular mechanisms of paradoxical growth suppression by over activation of oncogene kinases
  • 2019 - 2022 Analysis of the drug persistent cells to understand the acquired resistance mechanisms in lung cancer
Show all
Papers (94):
  • Shun Morino, Tetsuo Mashima, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer letters. 2024. 584. 216632-216632
  • Mingjue Chen, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, Shun Morino, Ayane Nakamura, Saori Inaba, et al. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British journal of cancer. 2023
  • Nobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, Ai Takemoto, Tomoko Oh-Hara, Ken Uchibori, Sophia Subat-Motoshi, Hironori Ninomiya, Kengo Takeuchi, Makoto Nishio, et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI insight. 2023
  • Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, et al. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science. 2023. 114. 9. 3698-3707
  • Mizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, Seiji Sakata, Ray Sagawa, Satoshi Takagi, Satoshi Nagayama, Kengo Takeuchi, Kazuhisa Takahashi, Ryohei Katayama. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer. Cancer immunology, immunotherapy : CII. 2023. 72. 9. 2971-2989
more...
MISC (33):
  • 片山量平, きょう博, 清谷一馬, 西尾誠人, 竹内賢吾, 藤田直也. 臨床検体と同系マウスゼノグラフトモデルを駆使した抗PD-L1抗体耐性機構の探索. 日本免疫治療学会学術集会プログラム・抄録集. 2020. 17th
  • Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, et al. Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
  • Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
  • 片山量平, キョウ ハク, 清谷一馬, 竹内賢吾, 西尾誠人, 藤田直也. 免疫チェックポイント阻害薬抵抗腫瘍の多様性と治療抵抗性機構の解析. 日本がん免疫学会総会プログラム・抄録集. 2019. 23rd
  • きょう博, 清谷一馬, 坂田征士, 西尾誠人, 竹内賢吾, 河本宏, 藤田直也, 片山量平. Secreted PD-L1 variants caused by aberrant splicing mediate anti-PD-L1 antibody resistance. 日本癌学会学術総会抄録集(Web). 2019. 78th
more...
Patents (10):
Education (3):
  • 2003 - 2006 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
  • 2001 - 2003 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
  • 1997 - 2001 The University of Tokyo Faculty of Pharmaceutical Sciences
Work history (5):
  • 2017/10 - 現在 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Chief
  • 2015/10 - 2017/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Senior Staff Scientist
  • 2012/07 - 2015/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Staff Scientist
  • 2010/04 - 2012/07 Massachusetts General Hospital Cancer Center Postdoc research fellow (JSPS fellowship)
  • 2006/04 - 2010/03 財団法人癌研究会 癌化学療法センター基礎研究部 研究員
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page